Kulig Grzegorz, Pilarska Krystyna, Kulig Jolanta, Robaczyk Maciej, Gromniak Elwira
Klinika Endokrynologii, Nadciśnienia, Tetniczego i Chorób Przemiany Materii, Pomorskiej Akademii Medycznej w Szczecinie.
Przegl Lek. 2004;61(12):1314-8.
The aim of this study is to evaluate serum concentrations of sELAM-1 in patients with Graves' orbitopathy (GO). We studied levels of soluble form of E selectin -1 in patients with euthyroid progressive GO (group I) and euthyroid stable GO (group II), hyperthyroid Graves' disease (GD) without GO (group III) and in healthy controls (group IV). sELAM-1 levels were measured by ELISA method. The highest serum levels of sELAM-1 were found in group III. Mean sELAM-1 concentrations in patients with progressive and stable GO were slightly lower than those in group III patients. The sELAM-1 serum concentrations in group I and II were comparable, nearly the same despite the different clinical picture of the disease in both groups. Mean serum concentrations of sELAM-1 decreased significantly during treatment of progressive GO, parallel to the improvement of the eye changes. In conclusion, sELAM-1 concentrations do not reflect the degree of GO activity. A significant decrease in sELAM-1 concentrations are associated with the efficient outcome of treatment. Increased sELAM-1 levels seem to result form both GO and GD.
本研究旨在评估格雷夫斯眼眶病（GO）患者血清中可溶性E选择素-1（sELAM-1）的浓度。我们研究了甲状腺功能正常的进行性GO患者（第一组）、甲状腺功能正常的稳定GO患者（第二组）、无GO的甲状腺功能亢进格雷夫斯病（GD）患者（第三组）以及健康对照者（第四组）的可溶性E选择素-1水平。采用酶联免疫吸附测定（ELISA）法检测sELAM-1水平。第三组患者的血清sELAM-1水平最高。进行性和稳定GO患者的sELAM-1平均浓度略低于第三组患者。第一组和第二组的sELAM-1血清浓度相当，尽管两组疾病临床表现不同，但几乎相同。在进行性GO的治疗过程中，sELAM-1的平均血清浓度显著下降，与眼部病变的改善同步。总之，sELAM-1浓度不能反映GO的活动程度。sELAM-1浓度的显著下降与治疗的有效结果相关。sELAM-1水平升高似乎是由GO和GD共同导致的。
